Boehringer Ingelheim achieves major milestone in chronic kid

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Germany , American , Katherine Tuttle , Coll Cardiol , Carinne Brouillon , J Nephrol Renovasc , Nlet Al , Prnewswire Boehringer Ingelheim , Animal Health , Kidney Research Institute , University Of Washington , Oxford Population Health , Nephrology Division , Boehringer Ingelheim , Boehringer Ingelheim Pharmaceuticals Inc , Braun , American Society Of Nephrology , Oxford Population , American Society , Kidney Week , Principal Study Investigator , Human Pharma , Corporate Headquarters , Ann Mtg , Diabetes Endocrinol , Ingelheim Pharmaceuticals ,